CN103923184A - Focal adhesion kinase inhibitor polypeptide and its application - Google Patents
Focal adhesion kinase inhibitor polypeptide and its application Download PDFInfo
- Publication number
- CN103923184A CN103923184A CN201410020874.3A CN201410020874A CN103923184A CN 103923184 A CN103923184 A CN 103923184A CN 201410020874 A CN201410020874 A CN 201410020874A CN 103923184 A CN103923184 A CN 103923184A
- Authority
- CN
- China
- Prior art keywords
- focal adhesion
- adhesion kinase
- polypeptide
- kinase inhibitor
- inhibitor polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the field of medicines, and concretely relates to a polypeptide having focal adhesion kinase inhibition activity and capable of treating acute lymphocytic leukemia. The sequence of the polypeptide is FRLCSHLRSEECVHW which is a brand new sequence, and the polypeptide can inhibit the focal adhesion kinase activity in vitro, can improve the survival rate of tumor-bearing mice in in-vivo tests, and has potential new drug exploitation values.
Description
Technical field
The present invention relates to focal adhesion kinase inhibitor polypeptide 3 and application, be specifically related to there is anti-adhesion spot kinase activity, treatment acute lymphoblastic leukemia polypeptide.
Background technology
Acute lymphoblastic leukemia (ALL) is a kind of carrying out property malignant disease, it is characterized by a large amount of lymphoblastic neocytes that is similar to.These cells can be found in blood, marrow, lymphoglandula, spleen and other organ.Acute lymphoblastic leukemia accounts for 80% of acute leukemia, and sickness rate peak is between 3 years old to 7 years old.ALL also can betide grownup, accounts for all grownups leukemic 20%.Along with the going deep into of medical research, the understanding of acute lymphoblastic leukemia and treatment are had made great progress in recent years.Wherein, focal adhesion kinase is being played the part of key player in acute lymphoblastic leukemia.
Focal adhesion kinase (focal adhesion kinase, FAK) is the non-receptor protein tyrosine kinase of a kind of kytoplasm, is a member of adhesion plaque mixture family (focal adhesion complex family).There is tyrosine kinase activity, after the stimulation that is subject to Oncoprotein and extracellular matrix-integrin, phosphorylation occurs.In addition, nervelet peptide, endothelin and beta-hypophamine etc. can make its phosphorylation FAK participate in many cell signal paths, and it is the maincenter of born of the same parents' internal/external signal transduction.It can integrate the signal from aspects such as the nutrition outside born of the same parents, pressure, cell adhesions, regulates the activity of downstream molecules, controls metabolism, the propagation of cell, or even the destiny of cell.In recent years research shows growth, grappling that FAK can regulating cell, move, cancerate and the process such as apoptosis, closely related with the generation of tumour.
The tumour that finds that there is at present FAK expression or increased activity has colorectal carcinoma, mammary cancer, thymic carcinoma, cancer of the stomach and glioblastoma multiforme and melanoma etc.The tumour cell of processing vitro culture with FAK specific inhibitor, can suppress propagation, growth, diffusion and the migration of cell.The FAK of phosphorylation and Src form complex body, can activate or suppress many downstream passages, comprise PI3K/Akt, RIP, p53 and RAS-Erk etc., and initial tumour occurs or cell death inducing.ShRNA technical finesse neuroblastoma cell discovery for Wu etc., FAK can suppress the cell migration of integrin A5B1 induction, and FAK can also be by its kinase domain activation Src.When mammary gland of mouse has lacked after FAK, do not affect the normal development of mammary epithelial cell, but the generation of the mammary cancer that can suppress to be excited by PyMT; Pound out the FAK of the human breast cancer cell of vitro culture, can stop growth, the inducing cell old and feeble (cell senescent) of cancer cells.With the competitive FAK of ATP and PYK2 inhibitor, as PF-562,271, PF-573,228 etc., process the tumour cell of vitro culture, can suppress cell migration.First phase clinical test results shows, FAK inhibitor has obvious therapeutic action to kinds of tumors.FAK is the key protein of the processes such as tumour generation, propagation, migration, and studying new specificity FAK inhibitor will be one of approach of cancer research and treatment.But at present there are no FAK inhibitor for treating acute lymphoblastic leukemia.
The focal adhesion kinase inhibitor that therefore, need to design high specificity is used for the treatment of acute lymphoblastic leukemia.Focal adhesion kinase inhibitor comprises macromole and small molecules.The preparation of macromole inhibitor and use have limited their development, and for example the Half-life in vivo of recombinant human focal adhesion kinase supressor is short.A lot of successfully micromolecular inhibitors, can be in nmole level the kinase whose vigor of anti-adhesion spot, but micromolecular inhibitor lacks specificity, if long-term use lacks specific focal adhesion kinase inhibitor and can produce larger side effect in chronic disease.Thereby from the application point of focal adhesion kinase inhibitor, the acute lymphoblastic leukemia of usining is correct selection as research object.At Acute response stage, body can tolerate inhibition short-term, focal adhesion kinase wide spectrum inhibitor Normal Physiological Function, makes the physiological structure of critical tissue's organ avoid destroying simultaneously, has increased chances of survival.
Focal adhesion kinase inhibitor polypeptide 3 in this patent has proved in acute lymphoblastic leukemia effective, has the prospect of developing in other tumor models.
Summary of the invention
goal of the invention
The invention provides brand-new sequence, this sequence focal adhesion kinase inhibitor, has good curative effect to acute lymphoblastic leukemia.
technical scheme
focal adhesion kinase inhibitor polypeptide 3, is characterized in that its sequence is FRLCSHLRSEECVHW.
The application of focal adhesion kinase inhibitor polypeptide 3 in treatment acute lymphoblastic leukemia medicine.
beneficial effect
Utilize solid-phase synthesis chemosynthesis focal adhesion kinase inhibitor polypeptide 3, this polypeptide has brand-new sequence, and this polypeptide can vitro inhibition focal adhesion kinase, treatment acute lymphoblastic leukemia.In endotoxin shock model experiment, successfully increased the survival rate of mouse.The peptide inhibitor that we find is anti-adhesion spot kinases vigor simultaneously, and in test, improves tumor-bearing mice survival rate in vivo, has potential new drug development and is worth.
Embodiment
Embodiment 1
The effect of 3 pairs of external focal adhesion kinase activity of focal adhesion kinase inhibitor polypeptide.
Get fresh cow brain tissue, peel off meninx and large blood vessel, shred, with cold MES damping fluid washing 1-2 time, with every Borneo camphor, organize the ratio of 0.5-1ml to add MES damping fluid, at 4 ℃, use electric homogenizer homogenate; 4 ℃, the centrifugal 1h of 105000g, gets supernatant, adds isopyknic microtubule polymerization damping fluid, 37 ℃ of water bath heat preservation 30min.26 ℃, the centrifugal 1h of 105000g, gets precipitation, adds the cold MES damping fluid of approximately 1/10 homogenate volume, stirs gently or with homogenizer, precipitation is pulverized; Suspension is put to ice bath 30min, precipitation is dissolved completely.By Lowry ' s method, measure protein content (SDS polyamide gels electrophoretic method).Focal adhesion kinase is diluted to 4-5mg/ml with MES damping fluid, puts in liquid nitrogen and preserves.Get freezing focal adhesion kinase solution, by normal-temperature water, rush its wall fast, make it to melt, put into ice bath, with MES damping fluid, be diluted to desired concn (2-3mg/ml), add ATP to 1mmol/l.The focal adhesion kinase solution at once taking out from ice bath of take is " 0 " point in spectrophotometer 350nm setting.Then cuvette is measured at 37 ℃ of temperature to the OD value of focal adhesion kinase solution, 20-30min, records temperature-light absorption value curve (T-OD curve), in triplicate continuously.
Inhibiting rate calculates: inhibiting rate (%)=(control tube " OD " value-chemical feed pipe " OD " value)/control tube " OD "
Experimental group is established five dosage: 0.75 μ M, 1.5 μ M, 3 μ M, 12 μ M, 24 μ M, and positive controls vincristine(VCR) dosage 3 μ M, blank group adds isopyknic solvent DMSO; Press aforesaid operations and measure light absorption value.As a result, with focal adhesion kinase inhibitor polypeptide 3 concentration, increase, inhibiting rate raises gradually, illustrates that anti-adhesion spot kinase activity constantly increases with the increase of drug level.
Embodiment 2
The growth of 3 pairs of cultured tumor cells in vitro of focal adhesion kinase inhibitor polypeptide and survival IC50.
Adopt MTT colorimetry.By the U937 cell of logarithmic growth, add in 96 well culture plates with 1.0 * 105, cultivate 24h, experimental port, positive drug control wells add respectively Experimental agents focal adhesion kinase inhibitor polypeptide 3 and the positive control medicine vincristine(VCR) of different concns; Blank group adds the solvent of same volume.Five multiple holes are established in every hole, cultivate 48h, respectively 0h, 2h, 8h, 14h, 20h, 24h, 36h,, the every hole of 48h adds MTT, after effect 4h, add DMSO, hatch 30min, at microplate reader 620nm place, measure absorbance A value, by formula growth of tumour cell inhibiting rate=(1-experimental group light absorption value/control group light absorption value) * 100%.The IC50 that calculates Experimental agents is 3.43 μ M.
Embodiment 3
With vigor in the body of tumor model detection focal adhesion kinase inhibitor polypeptide 3.
Set up U937 tumor model, positive control medicine vincristine(VCR); Blank group adds the solvent of same volume, and experimental group is established 3 dosage: 0.75,1.5 μ M, 3 μ M mg/Kg.After 21 days, observe mouse survival quantity, calculate survival rate.Result demonstration, focal adhesion kinase inhibitor polypeptide 3 can be protected small white mouse effectively, improves the survival rate of tumor-bearing mice, and survival rate reaches 73.2%.
SEQUENCE LISTING
<110> Nantong Chengxin Amino Acid Co., Ltd.
<120> focal adhesion kinase inhibitor polypeptide 3 and application thereof
<130>
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 15
<212> PRT
<213> artificial sequence
<400> 1
Phe Arg Leu Cys Ser His Leu Arg Ser Glu Glu Cys Val His Trp
1 5 10 15
Claims (2)
1. focal adhesion kinase inhibitor polypeptide 3, is characterized in that its sequence is FRLCSHLRSEECVHW.
2. the application of focal adhesion kinase inhibitor polypeptide 3 in treatment acute lymphoblastic leukemia medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410020874.3A CN103923184A (en) | 2014-01-17 | 2014-01-17 | Focal adhesion kinase inhibitor polypeptide and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410020874.3A CN103923184A (en) | 2014-01-17 | 2014-01-17 | Focal adhesion kinase inhibitor polypeptide and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103923184A true CN103923184A (en) | 2014-07-16 |
Family
ID=51141598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410020874.3A Pending CN103923184A (en) | 2014-01-17 | 2014-01-17 | Focal adhesion kinase inhibitor polypeptide and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103923184A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104292306A (en) * | 2014-09-22 | 2015-01-21 | 中国人民解放军第四军医大学 | Polypeptide ALKG and application thereof in drugs for treating leukaemia |
| CN105585618A (en) * | 2016-01-30 | 2016-05-18 | 苏州普罗达生物科技有限公司 | Focal adhesion kinase inhibitor polypeptide and application thereof |
| CN114605499A (en) * | 2022-04-07 | 2022-06-10 | 华中科技大学同济医学院附属协和医院 | Polypeptide RIP-18 capable of antagonizing RNA binding activity of RBSM1 protein and application thereof |
-
2014
- 2014-01-17 CN CN201410020874.3A patent/CN103923184A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 张文静: "局部黏着斑激酶作为肿瘤治疗靶点的研究进展", 《生命科学》 * |
| 阚玉玲: "急性白血病病人黏着斑激酶的表达及临床意义", 《齐鲁医学杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104292306A (en) * | 2014-09-22 | 2015-01-21 | 中国人民解放军第四军医大学 | Polypeptide ALKG and application thereof in drugs for treating leukaemia |
| CN104292306B (en) * | 2014-09-22 | 2017-07-25 | 中国人民解放军第四军医大学 | A kind of polypeptide A LKG and its application in treatment leukemia medicament |
| CN105585618A (en) * | 2016-01-30 | 2016-05-18 | 苏州普罗达生物科技有限公司 | Focal adhesion kinase inhibitor polypeptide and application thereof |
| CN114605499A (en) * | 2022-04-07 | 2022-06-10 | 华中科技大学同济医学院附属协和医院 | Polypeptide RIP-18 capable of antagonizing RNA binding activity of RBSM1 protein and application thereof |
| CN114605499B (en) * | 2022-04-07 | 2023-06-23 | 华中科技大学同济医学院附属协和医院 | Polypeptide RIP-18 capable of antagonizing RBSM1 protein RNA binding activity and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | The emerging role of CaMKII in cancer | |
| CN105848667A (en) | Peptide having angiogenesis inhibitory activity and composition containing same | |
| Wang et al. | Design, synthesis, and biological evaluation of 2, 4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities | |
| CN103923184A (en) | Focal adhesion kinase inhibitor polypeptide and its application | |
| Zhang et al. | Targeting death-associated protein kinases for treatment of human diseases: recent advances and future directions | |
| Pal et al. | Nitrogen‐Containing Heterocyclic Scaffolds as EGFR Inhibitors: Design Approaches, Molecular Docking, and Structure‐Activity Relationships | |
| CN103923187A (en) | Focal adhesion kinase inhibitor polypeptide and its application | |
| CN103739680B (en) | A kind of anti-adhesion spot kinase polypeptide and application thereof | |
| Yang et al. | Inhibition effects of 7-phloro-eckol from Ecklonia cava on metastasis and angiogenesis induced by hypoxia through regulation of AKT/mTOR and ERK signaling pathways | |
| Viana et al. | Targeting the heat shock response induced by modulated electro-hyperthermia (mEHT) in cancer | |
| CN103739678B (en) | Anti-adhesion spot kinase polypeptide and application thereof | |
| CN107987054A (en) | A kind of application of novel C DK2 inhibitor and its anti-breast cancer | |
| CN103923179A (en) | Focal adhesion kinase inhibitor polypeptide and its application | |
| CN103254287A (en) | Tubulin depolymerizing agent polypeptides and application thereof | |
| CN105585618A (en) | Focal adhesion kinase inhibitor polypeptide and application thereof | |
| CN103265621B (en) | Tubulin depolymerizing agent polypeptide and application thereof | |
| Paul et al. | Glioblastoma: Physiopathology and Complications | |
| CN103288926B (en) | Tubulin polymerization agent polypeptide and application thereof | |
| CN103351383B (en) | 5-fluorouracil nitroxyl-free-radical anti-tumor drug | |
| CN103254281B (en) | Tubulin polymerizing agent polypeptides 6 and application thereof | |
| CN103254282B (en) | Tubulin depolymerizing agent polypeptides 5 and application thereof | |
| CN103254289B (en) | Tubulin depolymerizing agent polypeptides and application thereof | |
| CN103254283B (en) | Tubulin polymerizing agent polypeptides and application thereof | |
| CN104693280A (en) | Signal-transducer-and-activator-of-transcription suppressing polypeptide and application thereof | |
| CN103304633A (en) | Tubulin polymerizing agent polypeptides 1 and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140716 |